Clinical Trial Update: Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating genetically modified T cells in combination with decitabine for recurrent or refractory ovarian, fallopian tube, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• Decitabine (Decitabine)
• Genetically Modified T Cells

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING